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ABSTRACT 
 
THE INVOLVEMENT OF CERAMIDE METABOLIZING GENES AND 
THEIR PRODUCTS IN DOCETAXEL INDUCED APOPTOSIS IN 
HUMAN PROSTATE CANCER CELLS 
 
Patients diagnosed with prostate cancer initially respond to androgen ablation 
therapy with tumor cells undergoing apoptosis, but then the patients relapse in time and 
develop metastatic, androgen independent prostate cancer.  
 Docetaxel has been widely used for treatment of patients with advanced 
metastatic prostate cancer. The sphingolipid, ceramide, is a lipid second messenger that 
mediates a lot of functions as regulation of cell growth, proliferation, differentiation, 
senescence and apoptotic responses in various cancer cells. The enzyme, 
glucosylceramide synthase (GCS) is responsible for bioactivation of the proapoptotic 
mediator ceramide to antiapoptotic glucosylceramide. Likewise, sphingosine kinase-1 
(SK-1) transforms apoptotic ceramide to antiapoptotic sphingosine 1-phosphate. 
Emerging results indicate that GCS and SK-1 are overexpressed in resistant cancer cell 
lines and cancerous tissue samples of patients. Moreover apoptosis and inhibition of cell 
proliferation and survival are induced by intracellular ceramide levels including 
enhancement in de novo ceramide production, exogenous delivery of cell permeable 
ceramide and inhibition of ceramide metabolism by affecting GCS and SK-1. 
 In this study, we applied exogenous ceramide and inhibitors of GCS and SK-1 in 
combination with docetaxel for sensitizing androgen independent prostate cancer cells 
to chemotherapy and provide their effectively utilization with minimizing side effects of 
the drugs. The de novo generation of ceramide is regulated by the genes (LASS1-6) in 
mammalian cells. Therefore in this study, we examined the possible roles of the 
ceramide/S1P and ceramide/GS by examining expression levels of GCS, SK-1 and 
LASS1,2,4,5,6 which can play important roles to overcome androgen independent 
prostate cancer both concurrently used chemotherapeutic agents and alone. 
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ÖZET 
 
PROSTAT KANSERİ HÜCRELERİNDE SERAMİD METABOLİZMASI 
GENLERİNİN VE ÜRÜNLERİNİN DOSETAKSELİN TETİKLEDİĞİ 
HÜCRE ÖLÜMLERİ ÜZERİNE ETKİSİ 
 
Prostat kanseri günümüzde erkeklerde görülen en sık malinite ve ikinci en sık 
ölüm nedenidir. Prostat kanseri hücreleri, standart androjen ablasyonu tedavisiyle ilk 
olarak apoptozise gitmelerine karşın, bazı hastalarda zamanla tedaviye direnç 
gelişmektedir.  
Prostat kanseri hastalarında dosetaksel kullanımının hastanın yaşam kalitesini ve 
süresini uzattığı tespit edilmiştir. Bir sfingolipid olan seramid, hücrede ikinci haberci 
olup, apoptozisi yönetir. Glukozilseramid sentaz (GSS) enzimi, proapoptotik bir 
molekül olan seramidin antiapoptotik glukozilseramide dönüşmesinden sorumludur. 
Benzer şekilde sfingozinkinaz-1 (SK-1), hücrede seramidi hücresel farklılaşma ve 
çoğalma sağladığı gösterilen antiapoptotik sfingozin1-fosfat’a dönüştürür. Daha önce 
yapılan çalışmalar, GSS ve SK-1’in bir çok tümor tipinde fazla miktarda bulunduğu ve 
kanser hücrelerinde direnç gelişimine katkısı olduğu gösterilmiştir. Çeşitli 
araştırmalarda, vücutta de novo seramid üretimi arttırmakla, dışarıdan hücre zarı 
geçirgenliği özelliği olan seramid analogları eklenerek ya da GSS ve/veya SK-1 yolu 
inhibe edilerek hücre içi seramid miktarının arttırıldığı gösterilmiştir. 
Araştırmamızda, androjenden bağımsız prostat kanseri hücrelerine dosetaksel ile 
beraber, seramid analoğu, GSS ve SK-1 inhibitörü uygulanararak hücre içi seramid 
seviyesinin artması sağlanmıştır, aynı zamanda dosetaksel ile kombinasyonu 
kullanılarak sinerjistik etkilerine bakılmıştır. Bu şekilde dosetakselin apoptotik 
etkinliğinin arttırılarak kullanım dozajının azaltılması ve yan etkilerinin minimize 
edilmesi hedeflenmiştir. Ceramidin de novo sentezi, memeli hücrelerinde LASS 1-6 
genleri tarafından regüle edilir. Çalışmamızda GSS, SK-1, ceramid/S1P, ceramid/GS, 
LASS1, 2, 4, 5, 6 genlerinin ekspresyon düzeyleri araştırılarak dosetaksel ile ve tek 
başlarına etkilerine bakılmış, androjenden bağımsız prostate kanser hücreleri üzerindeki 
rolleri araştırılmıştır.  
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 PROSTATE CANCER 
 
 
Prostate cancer is nowadays the most frequent non-skin cancer in the western 
industrialized countries and the second leading cause of death in men (Visakorpi 2003, 
Schulz, et al. 2003). Charles Huggins first found androgen ablation therapy that 
metastatic prostate cancer responds to androgen ablation therapy. However in 2 to 3 
year transition, androgen independent state occurs and results in more metastatic cancer 
and death. In addition, new invention on diagnosis with prostate specific antigen (PSA) 
testing increased prostate cancer incidence dramatically with early stage (Pienta and 
Smith 2005). Prostate cancer incidence increases with higher age and has a hereditary 
etiology. Accumulated data showed that incidence of prostate cancer occurrence is very 
high in man who have first degree relative with suffer from prostate cancer. Numerous 
studies have consistently reported that prostate cancer has a low incidence in Asians and 
highest in Scandinavians and African-Americans (Sakr, et al. 1998). Healthy 
consumptions of food and choices are also important in prostate cancer. Consciously 
consumption of diets by using specific fatty acids, antioxidant vitamins, carotenoids, 
and phytoestrogens may alter prostate cancer risk. Previous studies showed that changes 
in plasma levels of key hormones and associated molecules and naturally occurring 
variants in genes of the androgen also have a great importance. For instance, vitamin D, 
insulin-like growth factor 1 (IGF-1), and prostate cell growth regulatory pathways may 
affect prostate cancer risk.  
It is well known that the normal prostate is a composite tubulo-alveolar gland, as 
a chestnut size and encompasses the urethra, under the bladder, below the bladder neck 
localization (Lang, et al. 2009). In prostate, some regions are well defined as a first 
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origin of prostate cancer and benign prostatic hyperplasia. These distinct regions are 
composed of transition, central and peripheral zone (Abate-Shen and Shen 2000). 
Benign prostatic hyperplasia can be derived from transition and central zone. It is 
different from prostate cancer and can cause enlargement of the prostate gland which 
leads to urinary obstruction. The peripheral zone is the site for origin of 60-70% of the 
carcinomas (Schulz, et al. 2003). 
The normal growth and development of the prostate is stimulated by androgens 
such as testosterone and 5α-dihydrotestosterone (DHT). These hormones exert their 
growth stimulatory effect through binding to the intracellular androgen receptor (AR) 
(Chen, et al. 2008). The AR is a member of the steroid receptor hormone superfamily, 
and its gene is located on chromosome Xq11–12 (Gelmann 2002, Visakorpi 2003). The 
AR plays an important role on the initiation and growth of prostate cancers and in their 
reaction to therapy (Devlin and Mudryj 2009). Pituitary hormones, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH) influence releases testosterone from 
Leydig cells (Debes and Tindall 2002). Normally 90% of the testosterone is transformed 
to DHT intracellularly by the enzyme 5α-reductase.  
As a potent AR ligand, DHT cause a conformational change that releases heat 
shock proteins and allows receptor dimerization. The AR then bind to specific DNA 
binding sequences, known as AR response elements, in the promoter and enhancer 
regions of target genes. There is an assembly of multi-protein complexes under the 
influence of coactivator proteins and transcriptional activation and AR acts as a 
transcription factor (Dehm and Tindall 2006).  
Transition to androgen independent state after hormon therapy explained from 
different theories. The function of AR which is thought to be bypassed could be related 
with the AR or the development of alternative signaling pathways. Several target genes 
including those encoding PSA, insulin-like growth factor-1 (IGF-1), vascular 
endothelial growth factor (VEGF), and keratinocyte growth factor (KGF) are of great 
significance. These have been proved to play an important role in prostate cancer 
angiogenesis, metastases, and differentiation. In addition, a lot of hormones and 
cytokines have been shown to interact with the AR and influence transcription. Peptide 
growth factors such as KGF, IGF-1, and epidermal growth factor (EGF), IL-6, 
forskolin, cyclin E activate the AR in an androgen-deprived environment (Debes and 
Tindall 2002, Visakorpi 2003). In addition, after androgen ablation therapy, surviving 
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clonogenic tumor cells (stem cells) alter from an androgenic-dependent into an 
androgen-independent stage (Suzuki, et al. 2008). 
New treatment options are emerged to date for early stage prostate cancer. 
Surgery, radiotherapy can cure organ restricted carcinomas. Sometimes as primary 
therapy and complete ablation of the prostate, cryotherapy, for slow growing 
carcinomas watchful waiting and hormone therapy also has been utilized (Marberger, et 
al. 2008, Schulz, et al. 2003). Treatment decisions are of great significance in terms of 
patients and clinicians. It depends on bases of the stage of tumor, age and life 
expectancy.  If the patient diagnosed Gleason score of <7 and <10 year life expectancy, 
watchful-waiting is followed. For these type patients, treatment is not given but patient 
closely monitored (Heidenreich, et al. 2008).  
On the other hand the advantages of radiotherapy and radical prostatectomy are 
clear; the intention of treatment is usually curative. Although nearly 60% - 80% 
metastatic prostate cancer patients first respond well to hormone treatment in 2 years, 
more than 50% become androgen independent (Feldman and Feldman 2001, Yu, et al. 
2006). Metastasized prostate cancer can be treated with hormones, because most 
prostate cancers depend on androgens for their growth. Surgical or medical castration 
could contribute to improvement of bone pain, regression of soft-tissue metastases and 
diminish in serum PSA levels. However, tumor ultimately turns into androgen 
independent state, because most tumors will eventually gain mechanisms for 
independent growth (Korfage, et al. 2003). Currently, docetaxel (Doc) is advised from 
food and drug administration (FDA) in androgen independent prostate cancer 
(Madalinska, et al. 2001, Penson, et al. 2003). 
 
 
1.2. Molecular Biology of Prostate Cancer 
 
 
The phosphatase and tensin (PTEN) tumor suppressor gene is located on 10q23 
and is mutated more frequently in hormone refractory prostate cancer (Karayi and 
Markham 2004). PTEN mutation provides activation of the cascade, which provides 
cellular survival and known as a negative regulator of the phosphatidylinositol 3-kinase 
(PI3K) signaling cascade, protein kinase B (Akt) (Abate-Shen and Shen 2000, 
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DeMarzo, et al. 2003, Marandola, et al. 2004). It has also been implicated that lessened 
sensitivity to apoptosis and abnormal cellular proliferation is shown by the result of 
PTEN loss (Abate-Shen and Shen 2000). Moreover it is exhibited that PTEN function 
correlated with cell resistance to some drugs (Sherbakova, et al. 2008). Several studies 
have shown that prostate cancer progression raised Akt activity and loss of function of 
the cyclin dependent kinase 4 (CDK4) inhibitor, p27kip1 in advanced prostate cancer 
(Bott, et al. 2005).  Therefore, tumor invasiveness related to Akt is enhanced parallel 
with enhanced grade of cancer (Shukla, et al. 2007). Besides, Akt results in activation of 
the kinase mammalian target of rapamycin (mTOR) (Cao, et al. 2006, McCarty 2004) 
and several key proteins that are overexpressed as a consequence of this event include 
c-myc, cyclin D1, and VEGF. Although overexpression of cyclin D1 is uncommon in 
primary prostate tumors, it is also found in metastatic prostate cells (Abate-Shen and 
Shen 2000). Additional, NKX3-1 which is expressed in normal prostate epithelium is 
found decreased in prostate tumor cells (Lee, et al. 2008, DeMarzo, et al. 2003). One of 
the most important tumor suppressor gene glutathione S-transferase (GSTP1) is also 
demonstrated very frequent that looses of the activation by hypermethylation in prostate 
cancer (Hughes, et al. 2005, Wagenlehner, et al. 2007). 
Ras is thought to be the initiator of signaling in the Raf/MEK/ERK pathway 
regulated by binding to Ras. In a smaller group of advanced prostate cancer, 
extracellular regulated kinases (ERK) activation can be presented (Chatterjee 2003). 
Mutations in Ras gene are not common in prostate cancer cells (McCarty 2004, Karayi 
and Markham 2004). It is proved that a number of complex mixture of mutations that 
interrupt both cell cycle control and cell death pathways by activation of oncogenes and 
loss of tumor suppressor proteins. Frequently mutated cell cycle proteins not only at 
early but also in late stages of prostate cancer progression include Rb, p14, p16, p53 and 
p27 (Lee, et al. 2008). In metastatic or treatment-resistant disease, mutations of the p53 
gene are more commonly observed (Reynolds 2008). Abnormal or reduced expression 
of E-cadherin has been also associated with advanced stage and poor prognosis in 
human prostate cancer (Abate-Shen and Shen 2000, DeMarzo, et al. 2003). Therefore, 
HER-2/neu overexpression promotes androgen independent prostate cancer cells 
proliferation via the Bcl-2 up-regulation, activating AR in the absence of androgen 
cycle control deficiencies (Shi, et al. 2006).  
After all accumulation of multiple genetic deficiencies which result in tumor 
progression and somatic changes in suppressor genes occur in metastatic late phase 
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prostate cancer. Rb inactivation is common in metastatic and hormone refractory lesions 
and generally comes before the somatic modifications affecting the p53 and PTEN.  
Mutations of the Rb gene and loss of Rb protein expression have been described in both 
localized and more advanced prostate carcinomas (Abate-Shen and Shen. 2000). 
Interactions of these tumor suppressor genes thought to be very significant in terms of 
development of prostate cancer. Transition to a metastatic and hormone-insensitive state 
characterized by inadequate answer to chemotherapy may be result of increased levels 
of Bcl-2 protein (Gimba and Barcinski 2003). Overexpression of Bcl-2 in prostate 
cancer cells is a hallmark of advanced, hormone-refractory disease, and can be 
responsible for the resistance to apoptosis in late stages. Moreover, it has been shown 
that Bcl-2 can prevent activation of apoptosis of drugs related with the mechanisms 
which have microtubule assembly and disassembly functions. Thus it is also mentioned 
that Bcl-2 strongly connected with recurrence of this disease (Kaur, et al. 2004). 
 
 
1.3. Treatment Strategies for Prostate Cancer 
 
 
1.3.1. Chemotherapy for Androgen Independent Prostate Cancer 
               
 
Chemotherapy is known as a major choice for effective treatment for androgen 
independent prostate cancer (AIPC). Various clinical trials have exhibited the role of 
both single agent and combination chemotherapy in the treatment of AIPC. 
Encouraging results have gained from some of these trials related with PSA response, 
overall survival, and improvement in quality of life (Basler and Groettrup 2007). Since 
two decades, studies demonstrated that prostate cancer cells have susceptibility to 
mitotic spindle inhibitors including vinblastine, paclitaxel, and Doc.  
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1.3.2. Docetaxel 
 
 
Doc is a very effective and frequently used anticancer agent for the treatment of 
prostate cancer (Kish, et al. 2001, Schulz, et al. 2003). It is known as an inactive 
precursor and extracted from the needles of Taxus baccata. Doc as a semisynthetic 
taxane, likely has multiple antineoplastic activity functions (Basler and Groettrup 2007, 
Kraus, et al. 2003). Therefore, this most widely accepted mechanism of action involves 
binding of Doc to β-tubulin and helps polymerization impairs mitosis and thus retarding 
cell cycle progression in the G2/M phase and lead to the apoptosis (Ting, et al. 2007). 
Microtubules normally have a function as a cytoskeleton for the mitotic spindle in cell 
division. Thus they undergo polymerization in the attendance of microtubule related 
proteins. Doc inhibits microtubule depolymerization and microtubules can not be 
disassembled (Kolesnick, et al. 2007, Pienta and Smith 2005).  
 
 
 
Figure 1.1. Chemical structure of docetaxel. 
(Source: Docetaxel®, insert package) 
 
The cytotoxicity of Doc is also demonstrated by Bcl-2 phosphorylation and 
involving the activation of the c-Raf-1/Ras or the p53/p21WAF1/CIP1 signalling 
pathway (Fabbri, et al. 2006). In prostate cancer cells, Bcl-2 overexpression increases 
survival of prostate cancer cells and prevents apoptosis after androgen withdrawal and 
plays roles on both chemo- and androgen-resistance. Inactivation of Bcl-2 by 
phosphorylation results in decreased binding to the proapoptotic protein, Bax, which 
starts the process for caspase cascade and leading to apoptosis in the G2/M phase (Lee, 
et al. 2008). Besides, Bcl-2-negative tumors development can be inhibited by Doc 
inducing overexpression of the cell cycle inhibitor, p27. In advanced hormone 
 7
refractory prostate cancer cells, p27 is generally found less (Schrijvers 2007).  
Accumulating data have shown that there are a number of proapoptotic effects of Doc. 
For instance, induction of p53, Bcl-xL effects and their role on subdue multidrug 
resistance and antiangiogenic properties in Doc-induced apoptosis in cancer cells 
(Pienta and Smith 2005). At the moment, FDA approved Doc for the treatment of 
patients with advanced metastatic prostate cancer, and it does show a survival benefit.  
Consequently, from the clinical trials, it could be clearly concluded that Doc 
reduced PSA levels and relieved symptoms in patients diagnosed with AIPC (Petrylak 
2006, Fitzpatrick, et al. 2008). Therefore, promising researches could be new avenue by 
contribution underlying molecular mechanisms to max out its effectiveness of 
combination therapy with other agents. However, besides its known mechanisms related 
to microtubules and apoptosis other mechanisms of Doc-induced apoptosis including 
ceramide metabolizing genes and their end products, are unknown. 
 
 
1.4. Ceramide 
 
 
1.4.1. Sphingolipid Metabolism and the Sphingolipid Rheostat 
 
 
Ceramide can be generated via two ways. The first is de novo sythesis by serine 
and palmitate condensation to form 3-keto-dihydrosphingosine and acylation by a 
dihydro ceramide synthase (LASS or CerS) converted to dihydro-sphingosine, through 
the desaturation reaction (Hannun and Obeid 2008). In the second way, ceramide is 
generated by hydrolysation of the sphingomyelin via pH specific sphingomyelinases 
(acid SMase, neutral SMase, alkaline SMase). 
It was shown that both of these pathways could act as producing cellular signals 
and the major difference between these signaling routes are duration. Activation of 
SMase to form ceramide was illustrated within few minutes whereas de novo synthesis 
to produce ceramide in several hours (Morales, et al. 2007). Ceramide could be utilized 
in different sphingolipid pathways by phosphorilation by ceramide kinase, and 
glucosylation by glucosyl ceramide synthases or for biosynthesis of sphingomyelin by 
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receiving phosphocholine (Hannun and Obeid 2008). Ceramide is transported to the 
golgi apparatus to form sphingomyelin by ceramide transport protein (CERT) and also 
through vesicular transport to cytosolic side of golgi. After synthesis of 
glucosylceramide, it is transferred by transfer protein FAPP2, as a precursor for 
complex glycosphingolipids which are then transferred in small vesicles to the plasma 
membrane (Hannun and Obeid 2008, Venkatamaran and Futerman 2000). 
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Figure 1.2. The synthesis and metabolism of sphingolipids 
(Source: Pettus, et al. 2002) 
 
Degradation of simple sphingolipids, such as sphingomyelin and ceramide, 
mainly takes places within the acidic late endosomes and lysosomes as well as in the 
non-lysosomal compartments such as the caveolae in the plasma membrane (Zeidan and 
Hannun 2007). In lysosomes, acidic SMase hydrolyses sphingomyelin to yield 
phosphocholine and ceramide. Ceramide is subsequently degraded by the acidic 
ceramidase to the sphingosine backbone and a fatty acid. In non-lysosomal 
compartments sphingomyelin is degraded into ceramide by secreted acidic SMase. 
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Thereafter, ceramide is deacylated to sphingosine and reutilized for glycolipid 
formation (Huwiler, et al. 2000). Alternatively, sphingosine can be first phosphorylated 
at the 1-hydroxyl group and subsequently cleaved by a lyase into a long chain aldehyde 
and ethanolamine phosphate (Huwiler, et al. 2000). 
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Figure 1.3. Stress factors influencing ceramide metabolism  
(Source: Hannun, et al. 2008) 
 
Ceramides are influenced from a number of stress factors such as cytokines (tumor 
necrosis factor-α and Fas), environmental stress (heat and hypoxia), radiation (UV and 
ionization), and chemotherapeutics (Fillet, et al. 2003). Exogenous sphingomyelinase or 
ceramide induced NF-kB activation has been known (Fillet, et al.2003) as well as 
selective induction of the stress activated protein kinases (SAPK/JNK) pathway such as 
JNK, PKC, kinase suppressors of Ras (KSR), and protein phosphatases, such as protein 
phosphatase 2A (PP2A) and PP1 and ceramide activated protein phosphotases (Chen, et 
al. 2008). After activation of PP2A and PP1 via ceramide, dephosphorylation happens 
to Bcl-2, Akt, retinoblastoma (RB), c-Jun, and the nuclear serine/arginine-rich domain 
proteins (Modrak, et al 2006). Researches showed that ceramide has been demonstrated 
to activate PKCζ, the kinase KSR and cathepsin D (Ogretmen and Hannun 2004). 
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Therefore ceramide directly activates PKCζ (Lu and Wong 2004). It has been shown to 
be involved in inhibition of AKT.  
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Figure 1.4. General structure of sphingolipids 
 
Accordingly, as a possible therapeutic agent, ceramide could be used in tumor 
cells to trigger apoptosis. Cell permeable ceramide analogs have been developed for this 
purpose (Macchia, et al. 2003). It was shown that short-chain cell-permeable ceramide 
have antiproliferative and proapoptotic effects in numerous tumor cell types in vitro 
(Devalapally, et al. 2007). Consistent with the general idea that ceramide is a mediator 
of apoptosis and lack of ceramide generation has been linked to tumor cell resistance to 
death (Senchenkov, et al. 2001). Moreover, chemotherapy and radiotherapy bring out an 
increase in endogenous ceramide levels before the first biochemical signs of apoptosis 
and radio-resistant cell lines have been shown not to generate ceramide after irradiation 
of chemotherapy. 
 
 
1.4.2. LASS Genes and Ceramide Sythhase 
 
 
  The de novo synthesis of ceramide is regulated in mammals by LASS (longevity 
assurance homologues) genes. First of all, two genes, Lag l and its homologue Lacl 
genes identified from Saccharomyces cerevisiae and this is proved to be necessary for 
ceramide synthesis. It is found that actually all members of the LASS family of proteins 
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have resembling in their transmembrane profiles (Spassieva, et al. 2006). Membrane 
localization of some of the members, including yeast Lac1p (longevity assurance gene 
cognate 1) motif is required for (dihydro)ceramide synthase activity of LASS proteins 
and they share the same amino acids in the motif. Mammalian LASS1, LASS4, LASS5, 
and LASS6 genes are established to be in the endoplasmic reticulum cytoplasmic 
leaflet.  
Ceramides containing different fatty acids may play distinct roles in specific cell 
functions. It has been well documented previously that LASS1 regulates C18 ceramide 
and weakly C-20 ceramide, LASS2 and LASS4 enhances both C-22 and C-24 
ceramides with longer chain lengths and LASS5 and LASS6 synthesize C-14 and C-16 
and weakly C-12 and C-18 ceramides. LASS5 also shows C-18:1 ceramide synthesis 
different from LASS6 (Baran, et al. 2007, Mizutani, et al.2005). LASS genes also have 
different activities in different regions of tissues. As an illustrated in mouse, LASS1 is 
found mostly in brain, LASS2 in liver and kidney, LASS3 is found to be testis specific, 
LASS4 in skin, LASS5 in testis and kidney, LASS6 is found to be expressed in kidney 
and brain (Mizutani, et al. 2005, Mizutani, et al. 2006). By different fatty acids, it could 
be regulated distinct functions in specific cell regions. It also remains to be evolved. 
 
 
 
Figure 1.5. General structure of a ceramide  
(Source: Siskind, et al. 2003) 
 
In de novo synthesis pathway condensation of serine and palmtoyl-CoA results 
in 3-ketosphingosine and then sphinganine occurs by 3- ketosphinganine reductase. It is 
continue with the dihydroceramide synthase enzyme and dihydroceramide can be 
converted to ceramide by the introduction of a double bond between C4 and C5 on the 
sphingoid base catalyzed by dihydro ceramide desaturase (Matmati and Hannun 2008). 
In mammals, biosynthesis of ceramide is happened in the endoplasmic reticulum but to 
form glucosylceramide (GlcCer) or phosphocholine to generate sphingomyelin (SM) 
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occurs in the Golgi. Further glycosylation steps of GlcCer also operate in the Golgi 
(Sabourdy, et al. 2008). 
 
 
1.4.3 Sphingosine-1-Phosphate 
 
 
Ceramide hydrolyses to form sphingosine (Sph) by the enzyme ceramidase and 
after the generation of Sph, it is phosphorylated to sphingosine-1-phosphate (S1P) 
through the action of SK-1. Since this is the only pathway to form Sph, ceramidases 
also play an important role in this regulation (Mao and Obeid 2008). 
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Figure 1.6. The sphingolipid rheostat 
 
  The balance between the levels of ceramide and S1P is very crucial in terms of 
SK-1 activity. S1P is known as a powerful anti-apoptotic molecule. SKs and S1P play 
very important roles on regulating many cellular responses including mitogenic 
signaling, chemotaxis, cytokine/chemokine generation, intracellular calcium signals, 
tumor metastasis, angiogenesis, and autoimmune diseases. It is thought that S1P is 
yielded at the inner leaflet of the plasma membrane in response to tumor necrosis 
factor-α (TNFα), and SK-1 is activated in a mechanism that is dependent on TRAF 
(TNFα receptor-associated factor) and ERK (Hannun and Obeid 2008). S1P acts by 
binding to cell surface receptors to activate them which are known as G protein coupled 
receptors with five subtypes S1P1-S1P5. Sphingosine kinases are encoded by two 
genes, SK-1 and SK-2. SK-1 and its product S1P are related with cancer cell survival. 
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Up to now, to reduce S1P activities, SK-1 and SK-2 enzyme inhibitors or unspecific 
compounds were used in researches and promising results encourage developing novel 
drugs as a potential therapeutic in the future (Huwiler and Pfeilschifter 2008, Melendez 
2008). SK inhibitors rapidly promote the intrinsic apoptotic pathway via mitochondrial 
distribution (Leroux, et al.2007).  
SK-1 and S1P play a role on inflamation and tumor immunology. Recent studies 
have shown that S1P1R presents at high levels on endothelial cells and is known to have 
important roles in angiogenesis. Thus, it is shown that by inhibiting COX-2, tumor size 
and metastasize distribution can be decreased (Melendez 2008). It has been reported 
that S1P can transactivate VEGF receptors in endothelial cells and could be responsible 
for release of pro-angiogenic cytokines, VEGF and IL-8 (Visentin, et al. 2006). 
Moreover, recent evidence suggested that p53 upregulation can increase the 
synthesis of ceramide but decrease the synthesis of S1P (Panjarian, et al. 2008). Many 
growth factors, such as epidermal growth factor and platelet-derived growth factor, as 
well as the cytokines TNFα and IL-1, activate SK-1, resulting in transient elevations in 
the levels of S1P. This stimulation requires PKC, phospholipase D (PLD) and/or the 
extracellular signal-regulated kinase (ERK) MAPKs, which act upstream of SK-1 
(Pitson, et al. 2003). PKC may act directly or indirectly through PLD and ERK, whereas 
it has been proposed that ERK directly phosphorylates SK-1 on residue Ser225 (Pitson, 
et al. 2003), which is required for its translocation to the plasma membrane. PLD 
generates phosphatidic acid, which may directly bind SK-1 and lead to its membrane 
association. Actually, transporting S1P from the inner leaflet of the plasma membrane 
to the cell exterior is performed through the ABC transporter ABCC1 (Hannun and 
Obeid 2008). 
 
 
1.4.4 Glucosyl Ceramide Synthase 
 
 
Specialized glucosyltransferases transfer a glucose residue in a α-glycosidic 
linkage to the Cl-hydroxyl of ceramide to produce glucosylceramide (GCS). Golgi is the 
main side of the synthesis of the glucosylceramidesynthase. This process is happened on 
the cytosolic surface of the Golgi (Morales, et al. 2007). The enzyme glucosylceramide 
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synthase, responsible for conversion of the apoptotic ceramide to an antiapoptotic 
glucosylceramide is characteristically overexpressed in many drug resistant tumors 
(Kiguchi, et al. 2006). Moreover, it is found that in breast cancer and other cancer cells, 
the expression of the drug resistance ABC transporter P-glycoprotein is related with 
GCS expression and drug resistance (Zeidan and Hannun 2007). Thus, it is 
demonstrated that multidrug resistant cancer cells contain high level of 
glucosylceramide (GlcCer) than drug-sensitive cells. The drug resistance pump, MDR1, 
is one of the transporters for GlcCer, interestingly involved in occurrence of neutral 
glycosphingolipids (Merrill, et al. 2007). Involved with proliferation, oncogenic 
transformation, differentiation and tumor metastasis, GlcCer and its derivatives are of 
great importance. Therefore, it is found that glucosylceramide synthase regulates 
cytotoxic response to chemotheraphy (Gouaze-Andersson, et al. 2007).  
 
 
1.5. Aim of the Study 
 
 
For a long time, androgen dependence and insensitivity were the main issues in 
prostate cancer research and prostate cancer. It is expected to reveal insights into the 
molecular mechanisms of carcinogenesis to aid prevention. As ceramide mediates 
antiproliferative responses, whereas S1P and GlcCer enhance several tumor-promoting 
responses, strategies that either mimic/antagonize these sphingolipids or modulate their 
levels could provide a novel avenue for cancer therapy. Similarly, modulating these 
pathways might enhance drug action, overcome drug resistance, protect normal cells 
from cytotoxic actions, and even create new strategies for chemoprevention. Taken 
together, mounting evidence points to close connections between cytotoxic agents and 
ceramide metabolism. This investigation may also show a promising clinical potential 
for this therapeutic strategy to increase chemotherapeutic efficacy.  
The main objectives of the project are to examine the apoptotic pathways 
induced by Doc alone and/or in combination with specific chemicals which manipulate 
ceramide metabolism such as GCS inhibitor (PDMP), SK-1 inhibitor, exogenous C:8 
ceramide in hormone resistant prostate cancer cells. Then, evaluating the involvement 
of ceramide metabolizing genes and their products in Doc-induced apoptosis in DU-145 
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and PC-3 cells, we aimed to increase the sensitivity of prostate cancer cells to Doc by 
targeting ceramide metabolizing genes and enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16
CHAPTER 2 
 
 
MATERIALS & METHODS 
 
 
2.1. Chemicals 
 
 
The androgen independent prostate cancer cell lines, PC-3 and DU145, were 
obtained from German Collection of Microorganisms and Cell Cultures, Germany. 
RPMI1640, heat-inactivated fetal bovine serum (FBS), L-glutamine, penicillin-
streptomycin and trypsin EDTA were obtained from Biological Industries, Israel. Doc 
was obtained from Gulhane Medical School, Department of Hematology, Ankara, 
Turkey. SK-1 inhibitor was obtained from Cayman Chemical, USA. C:8 ceramide was 
obtained from Cayman Chemical, USA. GCS inhibitor, ((±)-threo-1-Phenyl-2-
decanoylamino-3-morpholino-1-propanolhydrochloride C23H38N2O3·HCl) (PDMP) 
and all other chemicals were obtained Cayman Chemical, USA. RNeasy RNA isolation 
kit, QIAquick gel extraction kit, Taq DNA Polymerase was obtained from Finnzymes, 
FI. Bradford dye, 4-5 % SDS polyacrylamide gel, coommasie blue, tween-20, 10X tris-
glycine-EDTA were obtained from Sigma, USA. dNTP set, DNA ladder was obtained 
from AMRESCO, USA. Caspase-3 colorometric assay kit was obtained from 
BioVision, USA. JC-1 mitiochondrial membrane potential detection kit was obtained 
from APO LOGICTM JC-1 from BACHEM, USA. Reverse-Transcription system and 
bovine serum albumine (BSA), trypan blue solution, β-mercaptoethanol, dimethyl 
sulfoxide (DMSO), agarose were obtained from Sigma, USA. 25 cm2 and 75 cm2 tissue 
culture flasks were obtained from Corning, USA. 
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2.2. Cell lines, Culture Conditions and Maintenance 
 
 
PC-3 and DU145 cells were cultured in RPMI1640 supplemented with 15% 
heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin-
streptomycin. The cells were maintained in CO2 incubator in the presence 5% CO2 at 37 
˚C. Medium was refreshed in every 3 days. For maintenance of DU-145 and PC-3 cells 
suspension on adherent cells was removed from the tissue culture flask. After 5 min 
incubation with 4mL trypsin EDTA, cell suspension was taken from tissue culture flask 
into a sterile falcon tube and equal amount of RPMI1640 was added. The cells were 
centrifuged at 1,000 rpm for 10 min. After centrifugation, supernatant was removed and 
the pellet was resuspended in 15mL of RPMI1640 and transferred into a sterile 75 cm2 
tissue culture flask. 
 
 
2.3. Thawing the Frozen Cells 
 
 
Cells were removed from frozen storage and quickly thawed in a 37 ۫C water 
bath to obtain the highest percentage of viable cells. When the ice crystals melted, the 
content was quickly taken into a sterile falcon tube and washed with PBS. Then the 
cells were cultured in 25 cm2 tissue culture flask in RPMI1640 medium. 
 
 
2.4. Cell Viability Assay 
  
 
Viable cells normally impermeable to trypan blue dye. Breakdown in membrane 
integrity cause the uptake of a dye in to cell. Cells will be observed and counted under 
microscope by using hemocytometer and calculated the percentage of unstained cells. 
Before each experiment, cell viability assay was conducted. 
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2.5. Cell Proliferation Assay 
 
 
The effect of different concentrations of Doc and other chemicals on PC-3 and 
DU145 cell lines were evaluated by using XTT Cell Proliferation Kit II (Biological 
Industries, Israel). Cells at a concentration of 104 cells/well were plated in a 96-well 
plate in 200 µl culture medium after verifying cell viability by trypan blue exclusion 
test. After 72 hours incubation, 40 µl of XTT labeling mixture were added to each well. 
The optical density was measured at 492 nm with a reference wavelength at 650 nm in a 
microplate reader (Multimode Reader).  
 
 
2.6. Evaluation of Apoptosis 
 
 
2.6.1. Determination of Caspase-3 Enzyme Activity  
 
 
Apoptotic effects of applied C:8 ceramide, GCS and SK-1 inhibitors alone or in 
combination with Doc were measured by caspase-3 colorimetric assay. Caspase-3 
enzyme activity was determined using the caspase-3 colorimetric assay (R&D Systems, 
USA). After lysis, cell extracts were used for caspase-3 enzyme activity by addition of a 
caspase-3 specific peptide that is conjugated to the color reporter molecule p-
nitroanaline (pNA). The cleavage of the peptide by the caspase releases the 
chromophore pNA, which can be quantitated spectrophotometrically at a wavelength of 
405 nm. The level of caspase enzymatic activity in the cell lysate is directly 
proportional to the color reaction. Caspase-3 activity levels were normalized to total 
protein amounts for each sample determined by Bradford Assay. Firstly, the cells 5x105 
in per well that had been induced to apoptosis were collected by centrifugation at 1000 
rpm for 10 min. Then, the collected cells were lysed by adding 100 ml of cold lysis 
buffer. After incubation of the cells on ice for 10 min, they were centrifuged at 14000 
rpm for 1 min. Supernatants were removed to new eppendorf tubes and the reaction 
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mixture was prepared in 96-well plates adding 20 ml assay buffer , 25 ml of sample, 50 
ml of sterilized water and 5 ml of caspase-3 colorimetric substrate. After 2 h incubation 
at 37 ˚C, the plate was read under 405 nm wavelength light (Thermo Electron 
Corporation Multiskan Spectrum, Finland). 
 
 
2.6.2. Detection of Mitochondrial Membrane Potential 
 
   
APO LOGIX JC-1 Assay Kit (Cell Technology, USA) was used to measure the 
mitochondrial membrane potential in DU-145 and PC-3 cells as described previously. 
JC-1, a unique cationic dye, was used to determine the loss of the MMP. In the 
beginning, the cells, the 5x105 for per well that had been induced to apoptosis were 
collected by centrifugation at 1000 rpm for 10 min. Supernatants were removed and 500 
μl of JC-1 dye was added onto the pellets. After incubation at 37 ˚C in 5% CO2 for 15 
min, they were centrifuged at 1000 rpm for 5 min. Then, 2 ml of assay buffer was added 
onto the pellets which were centrifuged for 5 min at 1000 rpm. All pellets were 
resuspended with 500 ml assay buffer and 150 ml from each of them was added into the 
96-well plate. The aggregate red form has absorption/emission maxima of 585/590 nm 
and the green monomeric form has absorption/emission maxima of 510/527 nm. The 
plate was read in these wavelengths by fluorescence Elisa reader (Thermo Varioskan 
Spectrum, Finland). 
 
 
2.6.3. Total RNA Isolation from Cells and PCR 
 
 
The role of ceramide metabolizing genes in Doc induced apoptosis were 
investigated by examining mRNA levels of SK-1, GCS, LASS 1, 2, 3, 4, 5, 6 in human 
prostate cancer cells exposed to different concentrations of Doc for 72 h. Total RNA’s 
were extracted using RNA Isolation Kit (Macherey-Nagel) as described by 
manufacturer and eluted in DEPC-treated materials. Recovered RNA concentration was 
measured by Nanodrop ND-1000 (260/280 and 260/230 ratios). 1 gμ  of total RNA was 
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reverse transcribed using reverse transcriptase enzyme (Moroney Murine Leukemia 
Virus Reverse Transcriptase, Fermentas, USA). After 1 h incubation at 50 ˚C, the 
reactions were stopped at 95 C˚ for 5 min (Table 2.2). The resulting total cDNA was 
used in PCR to measure the mRNA levels of LASS 1, 2, 3, 4, 5, 6, SK-1, GCS and β 
actin, as internal positive control. PCR mixture was prepared in the sterile 0.5 mL 
eppendorf tubes (Table 2.3). Amplification conditions were maintained in 35 cycles 
(Table 2.4.). The mRNA levels were quantified using the imaging system after running 
PCR products in agarose gels, followed by ethidium bromide staining. Primer sequences 
were given in Table 2.1. 
 
Table 2.1. Primers used in this study. 
 
 
 
 
 
 
 
 
 
GCS 5’ATGACAGAAAAAGTAGGCT3’ 
GCS 5’GGACACCCCTGAGTGGAA3’ 
LASS1 5’CTATACATGGACACCTGGCGCAA3’ 
LASS1 5’TCAGAAGCGCTTGTCCTTCACCA3’ 
LASS2 5’CCCTCGAGGGATGGATTACAAGGATGACGACGATAAGATGCTCCAGACCTTGTATGATT3’  
LASS2 5’CGGAATTCCGTCAGTCATTCTTACGATGGTT3’ 
LASS5 5’CCCTCGAGGGATGGATTACAAGGATGACGACGATAAGATGGCGACAGCAGCGCAGGGA3’  
LASS5 5’CGGAATTCCGTTACTCTTCAGCCCAGTAGCT3’ 
LASS6 5’CCCTCGAGGGATGGATTACAAGGATGACGACGATAAGATGGCAGGGATCTTAGCCTGG3’ 
LASS6 5’CGGAATTCCGTTAATCATCCATGGAGCAGGA3’ 
SK-1 5’CCGACGAGGACTTTGTGCTAAT3’ 
SK-1 5’GCCTGTCCCCCCAAAGCATAAC3’ 
β actin 5’CAGAGCAAGAGAGGCATCCT3’ 
β actin 5’TTGAAGGTCTCAAACATGAT3’ 
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Table 2.2. Ingredients of reverse transcription reaction. 
 
Ingredients Amount 
RNAse Free Water 5 μL 
Total RNA (5 μg) 5 μL 
10X Buffer 2 μL 
Random Primers (0.5 μg/L) 0.7 μL 
RNAse Inhibitor (50U/μL) 0,7 μL 
MgCl2 (25 mM) 4 μL 
dNTP (10 mM) 2 μL 
Moloney Murine Reverse Transcriptase enzyme (200 U/μL) 0.7 μL 
Total 20 μL 
 
 
Table 2.3. Ingredients of PCR solutions for LASS1, LASS2, LASS4, LASS5, LASS6,  
      SK-1, GCS genes. 
 
Reaction Mixture 
LASS1, LASS2, LASS4, LASS5, LASS6, 
SK-1, GCS, β Actin  
PCR grade water 37.7 
Reaction buffer (10x) 5 
MgCl2 (25 mM) 5 
dNTP (10 mM) 4 
Primer forward (25 pmol/μL) 1 
Primer reverse (25 pmol/μL) 1 
cDNA 1 
Taq DNA Polymerase 0.3 
Total Mixture 50 
 
 
 
 
 
 
 
 
 
 
 
 
 22
Table 2.4.Amplification conditions of LASS1, LASS2, LASS5, LASS6, SK-1, GCS, β 
     Actin. 
 
Steps Temperature Time 
Initial Denaturatin 94 ˚C 5 min 
Denaturation 94˚C 30 s 
Annealing 55˚C 45 s 
Extention 72˚C 1 min 
Final Extention 72˚C 5 min 
 
 
2.6.7. Statistical Analysis 
 
 
All experiments were set up in triplicate and the results were expressed as the mean + 
standard deviation (SD). Statistical analysis was performed using Student’s t-test or 
ANOVA and p<0.05 was considered significant. 
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CHAPTER 3 
 
 
RESULTS AND DISCUSSION 
 
 
3.1. Cell Proliferation Analysis on DU-145 and PC-3 cells 
 
 
3.1.1. Cytotoxic Effects of Doc  
 
 
Cytotoxic effects of Doc on DU-145 and PC-3 cells were examined by XTT cell 
proliferation assay. IC50 values of Doc were calculated from cell proliferation plots and 
were 30 nM and 38,4 nM in DU-145 (Figure 3.1) and PC-3 (Figure 3.2) cells exposed to 
increasing concentrations of Doc for 72 hours, respectively. 
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Figure 3.1. The cytotoxic effect of Doc on proliferation of DU-145 cells. 
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Figure 3.2. The cytotoxic effect of Doc on proliferation of PC-3 cells. 
 
 
3.1.2. Cytotoxic Effects of PDMP  
 
 
IC90 measures of both DU-145 (Figure 3.3) and PC-3 (Figure 3.4) cells were 
determined and found to be 100 µM and 85 µM respectively. 
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Figure 3.3. The cytotoxic effect of PDMP on proliferation of DU-145 cells. 
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Figure 3.4. The cytotoxic effect of PDMP on proliferation of PC-3 cells. 
 
 
3.1.3. Cytotoxic Effects of C:8 Ceramide 
 
 
We have observed a dose dependent cytotoxic effects of C:8 ceramide on both 
DU-145 and PC-3 cells. IC50 values of C:8 ceramide were found as 33 µM and 35 µM 
in DU-145 (Figure 3.5) and PC-3 (Figure 3.6) cells exposed to increasing concentration 
of C:8 ceramide for 72 hours, respectively. 
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Figure 3.5. The cytotoxic effect of C:8  ceramide on proliferation of DU-145 cells. 
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Figure 3.6. The cytotoxic effect of C:8  ceramide on proliferation of PC-3 cells. 
 
 
3.1.4. Cytotoxic Effects of SK-1 inhibitor 
 
 
The cytotoxic effects of SK-1 inhibitor also were found by using XTT assay. 
IC50 measurements of SK-1 inhibitor on DU-145 (Figure 3.7) and PC-3 (Figure 3.8) 
cells subsequent to 72 hours were found to be 32 and 92 µM respectively. 
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Figure 3.7. The cytotoxic effect of SK-1 inhibitor on proliferation of DU-145 cells. 
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Figure 3.8. The cytotoxic effect of SK-1 inhibitor on proliferation of PC-3 cells. 
 
 
3.1.5. Cytotoxic Effects of Combination of Doc/PDMP  
 
 
To show possible synergistic cytotoxic effects of Doc/PDMP combination on 
prostate cancer cells, we applied increasing concentrations of Doc with 100 μM PDMP 
for DU-145 and 85 μM PDMP for PC-3 cells. There were 10-, 44-, 70% and 25-, 44-, 
63% decreases in cell proliferation in 1-, 10-, 100 nM Doc exposed DU-145 and PC-3 
cells for 72 hours, respectively. On the other hand, 1-, 10-, 50- nM Doc with a 
combination of 100 µM PDMP decreased cellular proliferation 13-, 73- and 89% in 
DU-145 cells (Figure 3.9). Likewise on PC-3, the same concentration of Doc with 
combination of 85 µM PDMP reduced cellular proliferation 73-, 74-, 74% (Figure 
3.10). 
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Figure 3.9. Antiproliferative effects of Doc and PDMP combination on DU-145 cells. 
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Figure 3.10. Antiproliferative effects of Doc and PDMP combination on PC-3 cells. 
 
 
3.1.6. Cytotoxic Effects of Combination of Doc/C:8 Ceramide  
 
 
While there were 10-, 44-, and 70% or 25-, 44-, and 63% decreases in cell 
proliferation in 1-, 10-, and 100 nM Doc treated DU-145 or PC-3 cells the same 
concentration of Doc with a combination of 33 and 35 µM C:8 ceramide decreased 
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cellular proliferation 78-, 80-, and 81% or 61-, 66-, and 69% in DU-145 (Figure 3.11) 
and PC-3 cells (Figure 3.12) in the same order.  
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Figure 3.11. Antiproliferative effects of Doc and C:8 ceramide combination on DU-145 
         cells. 
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Figure 3.12. Antiproliferative effects of Doc and C:8 ceramide combination on PC-3 
                     cells. 
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3.1.7. Cytotoxic Effects of Combination of Doc/SK-1 inhibitor 
 
 
 When same concentration of Doc and 32 µM SK-1 inhibitor were incubated 
simultaneously in culture for 72 h, there were 77-, 77- and 79% decreases in 
proliferation of DU-145 cells comparing to untreated controls (Figure 3.13). Likewise 
on PC-3 cells, 0,1-, 1-, 10 nM Doc with combination of 92 µM SK-1 inhibitor reduced 
cellular proliferation 74-, 75-, 76% (Figure 3.14) respectively. 
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Figure 3.13. Antiproliferative effects of Doc and SK-1 inhibitor combination on DU145 
         cells. 
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Figure 3.14. Antiproliferative effects of Doc and SK-1 inhibitor combination on PC-3 
          cells. 
 
 
3.2. Evaluation of Apoptosis in DU-145 and PC-3 Cells     
  
 
3.2.1. Synergistic Apoptotic Effects of Doc and PDMP 
 
 
Treatment with Doc/PDMP combination caused a significant loss of 
mitochondrial membrane potential (MMP), as measured by increased accumulation of 
cytoplasmic/monomeric form of JC-1, in DU-145 and PC-3 cells as compared any agent 
alone. 
 There were 1.5- and 1.8-fold increase in cytoplasmic/monomeric JC-1 in 1- and 
10 nM Doc applied DU-145 cells, respectively, while 100 µM PDMP decreased MMP 
1.3 fold by itself. On the other hand, there were 1.8- and 2.6-fold increases in 
cytoplasmic/monomeric JC-1 in response to concentrations of Doc with 100 µM PDMP, 
respectively (Figure 3.15). 
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Figure 3.15. The changes in the MMP in DU-145 cells exposed to combination of  
                          Doc/PDMP. 
 
In parallel with these results, there were 1.0- and 1.1-fold increase in 
cytoplasmic/monomeric JC-1 in 1- and 10 nM Doc applied PC-3 cells, respectively. As 
shown in Figure 3.16, the same concentration of Doc in combination with 85 µM 
PDMP increased the cytoplasmic/monomeric JC-1 1.6- and 1.7- fold, respectively, as 
compared to untreated controls. 
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Figure 3.16. The changes in the MMP in PC-3 cells exposed to combination of  
                  Doc/PDMP. 
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In order to confirm these results, we determined the changes in caspase-3 
enzyme activity in the same experimental setups. There were 1.1- and 1.3-fold increases 
in 1- and 10 nM Doc alone applied DU-145 cells, respectively, while 100 µM PDMP 
did not change the caspase-3 enzyme activity as compared to untreated controls. Doc in 
combination with PDMP with same concentrations increased the enzyme activity 1.4- 
and 2.0-fold on DU-145cells, respectively (Figure 3.17). 
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Figure 3.17. The changes in caspase-3 enzyme activity in the Doc/PDMP applied 
   DU-145 cells. 
 
In addition, the same concentration, of Doc were applied to PC-3 cells and 1.6- 
and 2.4-fold increase observed in caspase-3 enzyme activity. Caspase-3 enzyme activity 
was 1.2-fold increased in response to only 85 µM PDMP application. Finally, 
significant synergistic results were observed on 1- and 10 nM Doc in combination with 
85 µM PDMP applied cells and the enzyme activity was raised 2.0- and 6.5-fold, 
respectively (Figure 3.18). 
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Figure 3.18. The changes in caspase-3 enzyme activity in Doc/PDMP applied  
      PC-3 cells. 
 
 
3.2.2. Synergistic Apoptotic Effects of Doc and C:8 Ceramide  
 
 
The combination of Doc and C:8 ceramide showed important increases in 
cytoplasmic/monomeric JC-1 in prostate cancer cells. There were 1.1- and 1.2-fold 
increase in cytoplasmic/monomeric JC-1 in 1- and 10 nM Doc applied DU-145 cells, 
respectively. While the application of 33 µM C:8 ceramide increased 
cytoplasmic/monomeric JC-1, 1.4 fold by itself, the same concentrations of Doc 
combination with 33 μM ceramide increased cytoplasmic/monomeric JC-1, 2.5- and 
2.7-fold, respectively (Figure 3.19). 
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Figure 3.19. The changes in the MMP in DU-145 cells exposed to combination of  
               Doc/C:8 ceramide. 
   
Likewise, 1.0- and 1.1-fold increases in cytoplasmic/monomeric JC-1 were 
found in response to 1- and 10 nM Doc on PC-3 cells.  While 35 µM C:8 ceramide 
increased cytoplasmic/monomeric JC-1, 1.2 fold by itself, there were 2.0- and 2.3-fold 
increases in cytoplasmic/monomeric JC-1 in PC-3 cells treated with combination of Doc 
and 35 µM C:8 ceramide (Figure 3.20) respectively. 
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Figure 3.20. The changes in the MMP in PC-3 cells exposed to combination of Doc/C:8 
         ceramide combination. 
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In parallel with MMP results, caspase-3 enzyme activity analyses showed that 
there were 1.0- and 1.3-fold increases in DU-145 cells as they treated with 1- and 10 
nM Doc, respectively. 33 µM C:8 ceramide were only increased the caspase-3 enzyme 
activity 1.1-fold. But Doc in combination with 33 µM C:8 ceramide increased the 
enzyme activity 1.7- and 2.1-fold (Figure 3.21) respectively. 
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Figure 3.21. The changes in caspase-3 enzyme activity in the Doc/C:8 ceramide applied    
         DU-145 cells. 
 
Furthermore, caspase-3 enzyme activity analyses presented that there were 1.1- 
and 1.3-fold increment in 1- and 10 nM Doc alone applied PC-3 cells, by the same 
order. Treatmet of PC-3 cells with Doc and 35 µM C:8 ceramide (35 µM) resulted in 
significant activation of caspase-3 (about  3.4- and 3.8-fold, respectively), whereas 
treatment with only C:8 ceramide at same concentration enhanced the caspase-3 enzyme 
activity 1.9-fold (Figure 3.22). 
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Figure 3.22. The changes in caspase-3 enzyme activity in the Doc/C:8 ceramide applied   
         PC-3 cells. 
 
 
3.2.3. Synergistic Apoptotic Effects of Doc and SK-1 Inhibitor 
 
 
 Increments of cytoplasmic/monomeric JC-1 in 1- and 10 nM Doc applied DU-
145 cells were found as 1.0- and 1.2-fold from previous data. Treatment of DU-145 
cells with 32 µM SK-1 inhibitor in the presence of 1- and 10 nM Doc also showed 
significant increases in cytoplasmic/monomeric JC-1 as 21.3- and 22.3-fold, 
respectively, compared to SK-1 inhibitor itself which was 15.3 fold (Figure 3.23). 
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Figure 3.23. The changes in the MMP in DU-145 cells exposed to combination of  
          Doc/SK-1 inhibitor.  
                     
To show effects of Doc and SK-1 inhibitor on MMP, we also detected changes 
in cytoplasmic/monomeric form of JC-1, on PC-3 cells. There were 1.0- and 1.3-fold 
increase in cytoplasmic/monomeric JC-1 in 1- and 10 nM Doc applied PC-3 cells, 
respectively. While 92 µM SK-1 inhibitor inceased cytoplasmic/monomeric form of JC-
1, 20.0 fold by itself. On the other hand, the same concentrations of Doc with 92 µM 
SK-1 inhibitor increased cytoplasmic/monomeric JC-1, 29.0- and 30.0-fold, 
respectively (Figure 3.24). 
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Figure 3.24. The changes in the MMP in PC-3 cells exposed to combination of  
         Doc/SK-1 inhibitor. 
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      Caspase-3 enzyme activity was also determined in DU-145 cells exposed to 
1- and 10 nM Doc or 32 µM SK-1 inhibitor. Results showed that there was around 1.0- 
and 1.1-fold increase in 1- and 10 nM Doc or 1.5-fold increase in 32 µM SK-1 applied 
DU-145 cells. On the other hand, the same concentrations of Doc in combination SK-1 
inhibitor increased the enzyme activity 2.4- and 3.0-fold (Figure 3.25), respectively. 
 
0
100
200
300
400
Co
ntr
ol
SK
-1 
Inh
.
Do
c (
1)
Do
c (
10
)
Do
c (
1) 
+ S
K1
 In
h
Do
c (
10
) +
 SK
1 I
nh
Docetaxel (nM) + SK1 Inh (uM), 72 h
%
 C
ha
ng
es
 in
 C
as
pa
se
-3
 A
ct
iv
ity DU-145
 
 
Figure 3.25. The changes in caspase-3 enzyme activity in the Doc/SK-1 inhibitor  
                     applied DU-145 cells.        
 
Similarly, raise on caspase-3 enzyme activity was also demonstrated on PC-3 
cells. Caspase-3 enzyme activity analyses showed that there were 1.3- and 1.4-fold 
increase in 1- and 10 nM Doc alone applied PC-3 cells, respectively. The same 
concentrations of Doc in combination with 92 µM SK-1 inhibitor increased the enzyme 
activity 2.3- and 2.4-fold, respectively by itself to untreated controls. SK-1 inhibitor 
increased the caspase-3 enzyme activity only 1.3-fold (Figure 3.26). 
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Figure 3.26. The changes in caspase-3 enzyme activity in the Doc/SK-1 inhibitor  
         applied PC-3 cells. 
 
 
3.3. Evaluation of PCR results 
 
 
We treated androgen independent DU-145 and PC-3 cells with increasing 
concentrations of Doc as 0,1-, 1-, 10- nM for 72 h to determine if Doc somehow effects 
expression levels of GCS, SK-1 and LASS genes (1, 2, 4, 5, 6). There were significant 
decreases in expression levels of GCS in response to elevation of Doc as compared to 
untreated controls and of course internal positive control, β actin (Figure 3.27.). 
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Figure 3.27. The expression levels of GCS in Doc treated DU145 and PC-3 cells. 
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normalized their levels to β actin levels. There were significant decreases in expression 
levels of SK-1 gene in both DU-145 and PC-3 cells in response to increasing 
concentration of Doc in a dose dependent manner (Figure 3.28.).  
 
         DU-145                       PC-3 
 
SK-1      
 
     
β actin 
 
 
 
 
 
 
Figure 3.28. The expression levels of SK-1 in Doc treated DU145 and PC-3 cells 
 
The expression levels of LASS1, -2, -4, -5, and -6 were determined by PCR in 
DU-145 and PC-3 cells exposed to 0,1-, 1-, 10- nM Doc for 72 h. PCR results revealed 
that there were significant increases in LASS1 gene expressions in dose-dependent 
manner as compared to untreated controls and normalized to β actin levels. On the other 
hand, LASS4 and LASS5 mRNA levels were declined when increased level of Doc 
concentration were applied in PC-3 cells. However there were increases in mRNA 
levels of LASS4 besides LASS5 expressions remain same in PC-3 cells. Thus, LASS2 
and LASS6 mRNA expressions have similar preferences and did not show any such 
increase in DU-145 but there were only weak increase in PC-3 cells in mRNA 
expressions of LASS2. However, there were not significant differences in response to 
increased doc concentration. All LASS mRNA expression results were compared with 
untreated controls and normalized to β actin. In summary, LASS family mRNA 
expressions each have distinct preferences for DU-145 and PC-3 cells, although with 
some overlap (Figure 3.29). 
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Figure 3.29. The expression levels of LASS 1, 2, 4, 5, 6 in Doc treated DU145 and PC-3 
               cells. 
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CHAPTER 4 
 
 
CONCLUSION 
 
 
For a long time, androgen dependence and insensitivity were the main issues in 
prostate cancer research. It is expected to reveal insights into the molecular mechanisms 
of carcinogenesis to aid prevention. As ceramide mediates antiproliferative responses, 
S1P and GlcCer enhance several tumor-promoting responces, strategies that either 
mimic/antagonize these sphingolipids or modulate their levels could provide a novel 
avenue for cancer therapy. Similarly, modulating these pathways might enhance drug 
action, overcome drug resistance, protect normal cells from cytotoxic actions, and even 
create new strategies for chemoprevention. Taken together, mounting evidence points to 
close connections between cytotoxic agents and ceramide metabolism.  
Bioactive sphingolipid ceramide involves in mediating anti-proliferative 
responses via various distinct mechanisms in human cancer cells. It has been well 
documented that treatment with some anticancer drug, results in increased generation 
and/or accumulation of endogenous ceramide either via the activation of the de novo 
pathway, or by increased activity of sphingomyelinases (Baran, et al. 2007). 
The way for treatment of cancer more than one agent is known as combination 
therapy. The main aim of the combination therapy is to get more effective result with at 
least two agents than any agent alone. For this purpose, several groups demonstrated 
that targeting the combination therapy increases the effect of one agent and it appears a 
very good alternative way for the treatment of cancer to protect some tissues from side 
effects of cancer therapy (Gore and Hermes-DeSantis 2008, Hind, et al. 2008). As 
known from the studies, chemotherapeutic agents induce apoptosis and they cause 
accumulation of ceramide during apoptosis in various cell types. In different cancer 
cells, arrangement of ceramide levels may enhance the effectiveness of some cancer 
therapies. From previous studies, it is known that ceramide usage with other anti-cancer 
agents importantly increased the apoptotic activity and therapeutic effectiveness in 
multidrug resistant tumor models. Therefore, Desai and friends exhibited that short 
chain ceramide coadministration with paclitaxel can important degree grow therapeutic 
efficacy in human ovarian adenocarcinoma cells and tumor models (Desai, et al. 2007). 
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To show enhancement of intracellular ceramide levels, many methods are used as 
exogenous delivery of cell permeable ceramide, and inhibition of ceramide metabolism 
by affecting GCS and SK-1 inhibitor.   
It has been well documented that low ceramide levels or with a defect in 
ceramide generation leads cancer cells more resistant to apoptosis (Macchia, et al. 
2003). Numbers of studies by using exogenous cell-permeable analogs of ceramide 
indicate evidence of their role in apoptosis (Akao, et al. 2002). Studies previously 
demonstrated that short-chain analog of ceramide is preferable since it has more water 
soluble characteristics than long-chain ceramides in experiments with cells in culture 
(Gomez-Munoz, et al. 2006). Short chain ceramide analogs are shown to be caused G0-
G1 cell-cycle arrest in most cancer cell lines. Develapally and friends recently showed 
that coadministration of ceramide with paclitaxel significantly enhanced apoptosis in 
both sensitive and multidrug resistant ovarian cancer cells (Develapally, et al. 2007). 
In order to potentiate the cytotoxicity of drugs, GCS inhibitor could be used for 
elevation of ceramide levels in various cancer cells (Reynolds 2004). Moreover in 
several cancer cells including in multidrug resistant melanoma, and resistant epidermoid 
and breast carcinoma cells, GlcCer was found and it is also believed that decreased the 
ceramide-mediated apoptotic signals, involving drug resistance (Modrak, et al. 2006, 
Ogretmen 2006). Thus, it was also shown that anti-androgen therapy in prostate cancer 
may accelerate ceramide levels by reducing the GCS levels (Radin, et al. 2003). 
Sphingosine kinase plays a significant role for the balance of sphingolipid 
rheostat, by transforming sphingosine to pro-survival S1P (Segui, et al. 2006). Other 
previous studies have showed that SK-1 expression is up-regulated in colon 
carcinogenesis and in the tumors of the patients with lung cancer. More importantly, it 
has been demonstrated previously that modulation of S1P levels increases apoptosis and 
perturbations in the metabolism of ceramide via overexpression of SK-1 may play 
important roles in the development of resistance to anticancer agents (Baran, et al. 
2007). Cyclooxygenase-2 expression function of SK-1 was also examined in colon 
carcinogenesis by Kawamori and co-workers and was found potential role of SK-1 to 
induction of carcinogenesis (Kawamori, et al. 2006).  Recently Le Scolan et al. reported 
that up-regulation of the expression of the sphingosine kinase gene was found 
associated with a leukemic process in vivo (Le Scolan, et al. 2005). Therefore Leroux 
and friends recently reported that in the study with unspecific SK inhibitor, DMPS, 
treated PC-3 cells which are enforced BCL-2 expression was not observed apoptotic 
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resistance (Leroux, et al. 2007). Another studies showed that besides its antitumor 
activity, SK inhibitors have identified as in the absence of toxicity to the animal in vivo 
(French, et al. 2003). As for the sphingolipid rheostat which is known as balance of 
S1P, ceramide is able to act as a sensitizer of tumor cell apoptosis induced by taxol 
(Huwiler and Zangemeister-Wittke 2007). The similar effects were shown by Pchejetski 
and friends established that in prostate cancer cells SK-1 inhibition correlates with Doc 
and camptothecin sensitivity (Pchejetski, et al. 2008). 
Several studies regarding ceramide-mediated apoptotic signaling have been 
reported. However, the mechanisms of ceramide-induced transcriptional regulation are 
less known. This study is the first to show that ceramide induces Doc with different 
agents which have an important role on ceramide biochemical pathways such as PDMP, 
ceramide analogue, C:8 ceramide, and SK-1 inhibitor. Therefore expression and the 
subsequent activation of LASS, GCS, and SK-1 genes were observed involved in Doc 
induced cell apoptosis.    
Doc is commonly used anticancer agent in prostate cancer patients. Their 
combination therapy was tried with GCS and SK-1 inhibitors and ceramide analog C:8 
ceramide. The signals inducing apoptosis could be blocked with S1P which mediate 
many important cellular processes including growth, survival, differentiation, 
angiogenesis and known proliferative effect on prostate cancer cells. In addition to its 
role as a mediator of cell death, and alterations in ceramide metabolism whereby pro-
apoptotic ceramide is converted to the antiapoptotic GlcCer and S1P have been found in 
a number of cancer cells and also related with resistance mechanism. In this manner, we 
used SK-1 inhibitor which specifically inhibits SK-1 and decreases intracellular 
concentrations of S1P. It is generally assumed that GCS inhibitors exert their 
chemosensitizing effect by potentiation of drug-induced intracellular ceramide 
elevation. Chemosensitization effects of PDMP, GCS inhibitor, and exogenously 
applied C:8 ceramide which provide synthesis or accumulation of ceramides were used 
in combination of Doc in DU-145 and PC-3 cells. 
In the first part of study, the roles and the mechanisms of action of ceramide 
metabolism in the regulation of Doc-induced cell death was investigated. PDMP/Doc, 
C:8 ceramide/Doc, and SK-1 inhibitor/Doc combinations enhanced apoptotic effect 
remarkably and found strongly synergistic. Cell viability and apoptotic assays also 
showed that PDMP, SK-1 inhibitor and C:8 ceramide in combination with Doc resulted 
in higher numbers of cells in apoptosis as compared to only Doc exposed cells. These 
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findings demonstrated that the ability to modulate ceramide metabolism might provide a 
new avenue by which drug sensitivity can be increased in androgen independent 
prostate cancer cells. 
At the second part of the investigation, to evaluate the role of ceramide 
metabolizing genes and their products in the apoptotic process in human prostate cancer 
cell lines, DU-145 and PC-3, treated with Doc. The data presented here showed in Doc 
induced apoptosis in androgen independent prostate cancer cells that the perturbations 
of the balance between proapoptotic ceramide and anti-apoptotic S1P, with opposing 
functions respectively, by downregulation of SK-1, and increased level of LASS1, play 
an important role in the regulation of mechanisms underlying on apoptosis. To examine 
the potential role of LASS/SK-1 on sphingolipid rheostat, in Doc induced apoptosis, 
first, the mRNA levels of LASS1, LASS2, LASS4, LASS5, LASS6, SK-1 and GCS 
were measured in DU-145 and PC-3 cells exposed to increasing concentrations of Doc 
compared with untreated controls. The additional strong support related our results that 
the ceramide increase due to de novo synthesis through LASS1 gene in a dose-
dependent manner as compared untreated cells. The data are also in agreement with the 
study showed that weak increase in LASS2 and LASS6 but inverse effect as a decrease 
in LASS4 and LASS5 genes on DU-145 and PC-3 cells. On the other hand, decreased 
expressions levels of SK-1 and GCS genes in response to Doc lead us to suggest that the 
sphingolipid rheostat changes on the behalf of ceramide accumulation via applied 
increased concentration Doc in androgen independent prostate cancer cells. It may offer 
a novel therapy that utilizes Doc combined with ceramide and/or agents affect ceramide 
metabolism in prostate cancer patients.  
In summary, our studies suggest that it has been long recognized that these 
findings hold major biological implications to tumor progression and therapy. In this 
manner, we hypothesize that exogenous ceramide, PDMP, a strong GCS inhibitor and, 
SK-1 inhibitor administration in a combination with Doc may induce apoptosis more 
than any agent alone. Targeting ceramide metabolism by increasing its synthesis and/or 
modulating its metabolism might provide improved strategies for the treatment of 
prostate cancer which has a high rate of incidence and has been accepted as incurable 
when it is androgen independent. Mounting evidence indicates a role for ceramide not 
only in tumor survival but also in tumor migration and invasion. Revealed novel 
molecular mechanisms of Doc with ceramide will bring new understandings and 
approaches to androgen independent prostate cancer therapies. 
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